

Next Science SPP Offer Opens

Sydney, Australia Friday, 4 March 2022, Next Science Limited (ASX:NXS) (**Next Science** or the **Company**) is pleased to announce the opening of the Next Science Share Purchase Plan Offer.

Next Science announced on 24 February 2022 that it would be undertaking a share purchase plan (**SPP**). The SPP is now open to eligible Next Science shareholders to apply for up to A\$30,000 of new fully paid ordinary shares in Next Science (**SPP Shares**) without incurring brokerage or other transaction costs.

The SPP follows the successful completion of an A\$6M (before costs) placement to institutional and sophisticated investors at an issue price of A\$0.90 per share and receipt of an additional A\$4M commitment from major shareholder Mr. Lang Walker (with completion conditional upon shareholder approval) as announced on 24 February 2022.

Eligibility

Shareholders are eligible to participate in the SPP if:

- (i) they had a registered address in Australia or New Zealand on Next Science's share register as at 7.00pm (Sydney time) on Wednesday, 23 February 2022; and
- (ii) if their registered address is in New Zealand, they continued to hold shares from the Record Date to the SPP Opening Date.

Shareholders who hold shares on behalf of, or who act for the account or benefit of, persons who reside outside Australia or New Zealand including persons who are in the United States, are not entitled to participate in the SPP.

The SPP Offer

SPP Shares are being offered at the lower of:

- (i) the issue price under the placement announced to the market on 24 February 2022 (being A\$0.90); and
- (ii) the price that is a 2% discount to the VWAP of Next Science shares on the ASX over the five trading days up to, and including, the closing date of the SPP (rounded down to the nearest cent).

The SPP is aiming to raise up to A\$5M (before costs). In the event of oversubscriptions, the SPP will be subject to a scale back of applications at the absolute discretion of the Company.

SPP Shares will rank equally with existing Next Science fully paid ordinary shares on issue.

Participation in the SPP is voluntary.

Offer Booklet

Participation in the SPP is subject to the terms and conditions set out in the SPP Offer Booklet. Eligible Shareholders are encouraged to read the Offer Booklet.

The Offer Booklet is attached and will be dispatched by email today to those shareholders who have elected to receive electronic communications and by post on Monday, to those shareholders who have not made such an election.

Eligible shareholders may apply online from today via the Next Science SPP Offer website at: https://investors.nextscience.com/investor-centre/

For further information about the SPP or how to participate in the SPP, please call the Next Science SPP hotline on 1300 365 790 between 8:30am to 5:30pm (AEDT), Monday to Friday from 4 March 2022.

Indicative Key Dates**

Event	Date 2022
Record date for eligible shareholders to subscribe for New Shares via the SPP Offer	7.00pm (Sydney time) Wednesday 23 February
Announcement of SPP	Thursday, 24 February
SPP Opening Date & SPP Offer Booklet dispatched to shareholders	Friday, 4 March
SPP Offer closes	Friday, 18 March unless extended
Announcement of results of SPP Offer	Wednesday, 23 March
Issue of New Shares under the SPP Offer and normal trading of New Shares issued under the SPP Offer commences	Tuesday, 29 March
Dispatch of holding statements	Thursday, 31 March
Shareholder meeting to approve issue of shares to Next Science substantial holder, Mr. Lang Walker	Friday, 27 May

^{**} These dates are indicative only and are subject to change. Next Science reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, Next Science reserves the right to amend the Closing Date, accept late applications under the SPP Offer (either generally or in particular cases), and to withdraw or vary the SPP Offer without prior notice. Any extension of the closing date will have a consequential effect on the date for the allotment and issue of New Shares.

Further information:

Judith Mitchell

Managing Director, Next Science Limited Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory Phone: +61 400 248 080

Email: mbrown@pegasusadvisorv.com.au

Approved and authorised for release by Next Science's Board of Directors.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary XBIOTM technology to reduce the impact of biofilm based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIOTM technology. For further information visit: www.nextscience.com.